Stifel raises 10X Genomics stock price target on Atera outlook
Stifel raised 10X Genomics' (TXG) price target to $68 from $50, citing strong Q3 results and increased Atera placement expectations. The stock has risen 347% over the past year, trading at $58.06. Analysts predict profitability this year with an EPS of $0.10, though the stock appears overvalued. Revenue was $150.66M, beating estimates, but margins are expected to decline due to Atera shipments.
How this was made
The 30-second read
Why it matters
The earnings beat combined with Stifel's target raise suggests a short‑term upside catalyst, though margin concerns could temper longer‑term gains.
Market read
Analyst target upgrade following earnings beat may drive buying pressure in TXG and related biotech stocks.
What to watch
Potential slowdown in AI adoption and competitive pressure from rival platforms.
Background
10X Genomics reported Q3 2026 results that beat expectations, with adjusted loss per share of $0.15 versus $0.26 expected and revenue of $150.66 million versus $147.93 million forecast.
Ticker impact
Stifel raised its price target on 10X Genomics to $68 from $50 after the company posted a Q3 earnings beat.
upward pressure as investors price in the higher target
The new $68 target reflects confidence in AI benefits and Atera adoption, likely prompting buying interest.
Market effects
Positive for the single‑cell genomics and biotech sector as the target raise highlights AI‑driven growth potential.
U.S. biotech stocks may see modest gains on the news.
Limited to investors tracking genomics and AI‑enabled biotech companies.
Counterpoint
The target may be optimistic given margin pressure from Atera shipments.
Key entities
- company10X Genomics
Developer of single‑cell analysis platforms.
- analyst_firmStifel
Equity research firm that raised the price target.
